Pharming Group (PHAR) has released an update.
Pharming Group N.V. reports a successful Annual General Meeting where shareholders approved key proposals, including the reappointment of Non-Executive Directors, updates to the Remuneration Policy, and authorizations for share issuance and repurchase. The company continues to focus on developing protein replacement therapies and precision medicines for rare diseases, with a global reach spanning over 30 markets.
For further insights into PHAR stock, check out TipRanks’ Stock Analysis page.
